Brain-accessible peptide reduces stroke damage by targeting TrkB-T1 receptor to modulate neuroinflammation
A brain-accessible peptide targeting the BDNF receptor TrkB-T1 specific interactome modulates the inflammatory response and reduces neurotoxicity in ischemic stroke, offering a new peptide-based approach to neuroprotection.
Quick Facts
What This Study Found
Brain-accessible peptide targets TrkB-T1 (truncated BDNF receptor). Modulates: glia reactivity, neuroinflammation, excitotoxicity. TrkB-T1 interactome-specific targeting. Reduces stroke damage. Novel neuroprotective approach.
Key Numbers
How They Did This
Ischemic stroke models. Brain-accessible peptide design targeting TrkB-T1 interactome. Neuroinflammation and neurotoxicity assessment.
Why This Research Matters
Stroke has limited treatment options beyond clot removal. A brain-accessible peptide that reduces inflammation and neurotoxicity through a novel target could provide neuroprotection during the critical post-stroke window.
The Bigger Picture
Targeting specific receptor isoform interactomes rather than the receptor itself is a sophisticated drug design strategy. If successful for stroke, this approach could extend to other neurodegenerative conditions.
What This Study Doesn't Tell Us
Preclinical study. Brain accessibility of the peptide needs clinical confirmation. TrkB-T1 interactome complexity. Stroke models may not fully replicate human disease.
Questions This Raises
- ?What is the peptide's brain penetration mechanism?
- ?Could this combine with tPA for comprehensive stroke treatment?
- ?Does targeting TrkB-T1 affect normal BDNF signaling?
Trust & Context
- Key Stat:
- New stroke neuroprotective peptide A brain-accessible peptide targeting TrkB-T1 receptor interactome modulates neuroinflammation and neurotoxicity in stroke—a novel approach to brain protection
- Evidence Grade:
- Preclinical mechanistic study. Novel target and approach.
- Study Age:
- Published in 2025.
- Original Title:
- A brain-accessible peptide modulates stroke inflammatory response and neurotoxicity by targeting BDNF-receptor TrkB-T1 specific interactome.
- Published In:
- Theranostics, 15(10), 4654-4672 (2025)
- Database ID:
- RPEP-13851
Evidence Hierarchy
Frequently Asked Questions
Could a peptide treat stroke?
This study developed a peptide that can reach the brain and reduce stroke damage by targeting a specific brain receptor (TrkB-T1). It reduced inflammation and neurotoxicity—the main processes that cause brain damage after a stroke. If confirmed in clinical trials, this could provide a new treatment option during the critical post-stroke window.
How is this different from current stroke treatments?
Current stroke treatment mainly involves removing the blood clot (tPA or thrombectomy). This peptide addresses a different problem: the inflammatory damage that continues after the clot is removed. Combining clot removal with neuroprotective peptide treatment could significantly improve stroke outcomes.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13851APA
Ugalde-Triviño, Lola; Tejeda, Gonzalo S; Esteban-Ortega, Gema M; Díaz-Guerra, Margarita. (2025). A brain-accessible peptide modulates stroke inflammatory response and neurotoxicity by targeting BDNF-receptor TrkB-T1 specific interactome.. Theranostics, 15(10), 4654-4672. https://doi.org/10.7150/thno.111272
MLA
Ugalde-Triviño, Lola, et al. "A brain-accessible peptide modulates stroke inflammatory response and neurotoxicity by targeting BDNF-receptor TrkB-T1 specific interactome.." Theranostics, 2025. https://doi.org/10.7150/thno.111272
RethinkPeptides
RethinkPeptides Research Database. "A brain-accessible peptide modulates stroke inflammatory res..." RPEP-13851. Retrieved from https://rethinkpeptides.com/research/ugalde-trivino-2025-a-brainaccessible-peptide-modulates
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.